Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Proteins from Avastin® (bevacizumab) Show Tyrosine Nitrations for which the Consequences Are Completely Unclear

  • Jia Wan ,

    Contributed equally to this work with: Jia Wan, Edina Csaszar, Wei-Qiang Chen

    Affiliation Department of Pediatrics, Medical University of Vienna, Vienna, Austria

  • Edina Csaszar ,

    Contributed equally to this work with: Jia Wan, Edina Csaszar, Wei-Qiang Chen

    Affiliation Mass Spectrometry Facility, Max F. Perutz Laboratories, Vienna, Austria

  • Wei-Qiang Chen ,

    Contributed equally to this work with: Jia Wan, Edina Csaszar, Wei-Qiang Chen

    Affiliation Department of Pediatrics, Medical University of Vienna, Vienna, Austria

  • Kongzhao Li,

    Affiliation Department of Pediatrics, Medical University of Vienna, Vienna, Austria

  • Gert Lubec

    gert.lubec@meduniwien.ac.at

    Affiliations Department of Pediatrics, Medical University of Vienna, Vienna, Austria, Mass Spectrometry Facility, Max F. Perutz Laboratories, Vienna, Austria

Proteins from Avastin® (bevacizumab) Show Tyrosine Nitrations for which the Consequences Are Completely Unclear

  • Jia Wan, 
  • Edina Csaszar, 
  • Wei-Qiang Chen, 
  • Kongzhao Li, 
  • Gert Lubec
PLOS
x

Abstract

Avastin® (bevacizumab) is a protein drug widely used for cancer treatment although its further use is questionable due to serious side effects reported. As no systematic proteomic study on posttranslational modifications (PTMs) was reported so far, it was the aim of the current study to use a gel-based proteomics method for determination of Avastin®-protein(s).

Avastin® was run on two-dimensional gel electrophoresis (2-DE), spots were picked, followed by multi-enzyme in-gel digestion. Subsequently, the resulting peptides and posttranslational modifications were identified by mass spectrometry (nano-LC-ESI-MS/MS; HCT and LTQ Orbitrap MS). Heavy and light chains were observed and the 9 spots that were picked from 2DE-gels were identified as bevacizumab with high sequence coverage. MS/MS results showed multiple tyrosine nitrations on the Avastin® light and heavy chains that were either represented as nitrotyrosine or as aminotyrosine, which was shown to be generated from nitrotyrosine under reducing conditions. Protein nitration is known to significantly change protein functions and interactions and it may well be that some of the adverse effects of the protein drug Avastin® may be due to this PTM, which may have been generated during production- thus, nitration of Avastin® is a challenge for the pharmaceutical industry.

Introduction

Avastin® (bevacizumab) is an antibody widely used in antitumor therapy with the underlying principle of neutralizing vascular endothelial growth factor (VEGF) thus moderating tumor growth. Although no final assessment of the effectiveness of bevacizumab in large cohorts of cancer patients has been published, it can be considered a therapeutic antibody with high potential [1]-[5].

Fatal adverse effects, however, have been reported in tumor patients treated with this protein drug and in according to a meta-analysis, bevacizumab therapy was associated with increased treatment-related mortality [6].

More specifically, bevacizumab treatment may significantly increase the risk of serious hemorrhage, hypertension, proteinuria, cardiac toxicity, vascular thromboembolism, gastrointestinal, dermatological and endocrine toxicity in cancer patients [7]-[15]. According to the statement by Stone et al. [10], toxicity management in treatment with anti-angiogenic agents has not been an endpoint in most studies carried out up to now and there is therefore a fundamental need for investigations that will generate more evidence-based practice guidelines.

Vascular side effects may be readily assigned to biological activity of VEGF inhibition directly whereas others may be due to other mechanisms, including probable modifications of this humanized antibody. No information on Avastin® protein modifications is available so far and the only systematic mass spectrometrical approach analysing Avastin® was not designed to characterise protein modifications but rather to determine stability [16].

The absence of this information formed the rationale for the current study with the aims to identify and characterise Avastin protein and protein modifications in order to form the basis for studies linking protein modifications to adverse side effects. And indeed, heavy tyrosine nitration, known to modify protein properties and functions, was observed in the commercially available medical product.

Materials and Methods

Avastin® was purchased from Roche, Basel, Switzerland, as manufactured by Genentech, Inc., San Francisco, USA (Batch number H0102B01).

Samples of 100 μg protein were applied on immobilized pH 3–10 nonlinear gradient strips. Focusing started at 200 V and the voltage was gradually increased to 8,000 V at 4 V/min and kept constant for a further 3 h (approximately 150,000 Vh totally). Prior to the second dimensional run, strips were equilibrated twice for 15 min with gentle shaking in 10 mL of SDS equilibration buffer (50 mM, pH 8.8, Tris-HCl, 6 M urea, 30% v/v glycerol, 2% w/v SDS, trace of bromophenol blue). DTT (1% w/v) was added at the first incubation for 15 min and 4% (w/v) iodoacetamide instead of DTT at the second incubation step for 15 min. The second-dimensional separation was performed on 10–16% gradient SDS-PAGE. After protein fixation for 12 h in 50% methanol and 10% acetic acid, gels were stained with colloidal Coomassie blue (Novex, San Diego, CA, USA) for 8 h and excess of dye was washed out from the gels with distilled water. Apparent molecular weights were determined by running precision protein standard markers (Bio-Rad Laboratories, Hercules, CA, USA), covering the range of 10–250 kDa and isoelectric points of the immobilized pH gradient strips were from 3-10 [17].

Sodium hydrosulfite treatment

In order to verify nitration [18], 50 mM sodium hydrosulfite (Na2S2O4) (Sigma, Germany) was added to Avastin® in its original solvent. The reaction mixture was stirred at 23°C for 30 min to convert 3-nitrotyrosine to 3-aminotyrosine. Subsequently buffer was exchanged by 25mM ammonium bicarbonate by Amicon Ultra 10K (Millipore, Billerca, US) 4 times.

In-gel digestion

Selected gel spots were picked for the investigation (Fig. 1). Gel pieces were put into a 1.5 mL tube and washed with 10 mM ammonium bicarbonate and 50% acetonitrile (ACN) in 10 mM ammonium bicarbonate repeatedly. Addition of ACN resulted in gel shrinking and the shrunk gel plugs were then dried in a Speedvac Concentrator (Eppendorf, Germany). Dried gel pieces were re-swollen and in-gel digested with 40 ng/μL trypsin (Promega, Madison, WI, USA) in digestion buffer (consisting of 5 mM octyl β-D-glucopyranoside (OGP) and 10 mM ammonium bicarbonate, pH 7.8) and incubated overnight at 37°C. Digestion with chymotrypsin (Roche Diagnostics), 25 ng/μL was done in 25 mM NH4HCO3 with 5 mM OGP (pH 7.8) at 30°C for 4 h. Digestion with 40 ng/μL Pepsin (Roche Diagnostics) was done in 0.1M HCL (pH 1) at 37°C for 4 h.

thumbnail
Figure 1. 2-DE image of Avastin® is shown providing assignments of identified protein spots.

https://doi.org/10.1371/journal.pone.0034511.g001

Peptide extractions were performed with 15 μL of 1% formic acid (FA) in 5 mM OGP for 30 min, 15 μL 0.1% FA for 30 min and 15 μL 0.1% FA in 20% ACN for 30 min. The extracted peptides were pooled for nano-LC-ESI-CID/ETD-MS/MS or LTQ orbitrap MS/MS analyses.

nano-LC-ESI-CID/ETD-MS/MS

The HPLC used was an Ultimate 3000 system (Dionex, Sunnyvale, CA, USA) equipped with a PepMap100 C-18 trap column (300 mm×5mm) and PepMap100 C-18 analytic column (75 mm×150 mm). The gradient was (A 50.1% FA in water, B 50.08% FA in ACN) 4–30% B from 0 to 105 min, 80% B from 105 to 110 min, 4% B from 110 to 125 min. An HCT ultra ETD II (Bruker Daltonics, Bremen, Germany) was used to record peptide spectra over the mass range of m/z 350–1500, and MS/MS spectra in information dependent data acquisition over the mass range of m/z 100–2800. Repeatedly, MS spectra were recorded followed by three data-dependent CID MS/MS spectra and three ETD MS/MS spectra generated from three highest intensity precursor ions. An active exclusion of 0.4 min after two spectra was used to detect low abundant peptides. The voltage between ion spray tip and spray shield was set to 1,500 V. Drying nitrogen gas was heated to 150°C and the flow rate was 10 L/min. The collision energy was set automatically according to the mass and charge state of the peptides chosen for fragmentation. Multiple charged peptides were chosen for MS/MS experiments due to their good fragmentation characteristics. MS/MS spectra were interpreted and peak lists were generated by DataAnalysis 4.0 (Bruker Daltonics).

Raw spectra were processed by Mascot Daemon 2.2.2 (Matrix Science Ltd, London, UK), the search engine was Mascot 2.2.04. Peptide tolerance was set to ±0.2Da, the MS/MS tolerance was set to 0.6 Da. Carbamidomethylcysteine was set as static, oxidation of methionine residues as variable modification. An in-house generated FASTA data base was used for the search containing the sequences of the Avastin® (http://www.pmda.go.jp/english/service/pdf/Abastin-Bevacizumab.pdf), common contaminants and proteolytic enzymes. The data base contained 330 sequences and 110,409 residues. Mascot identifications required at least ion scores greater than 20. PTM searches were also done using the Modiro® software with following parameters: enzyme selected as used with two maximum missing cleavage sites, a peptide mass tolerance of 0.2 Da for peptide tolerance, 0.6 Da for fragment mass tolerance, modification 1 of carbamidomethyl (C) and modification 2 of methionine oxidation. Searches for unknown mass shifts, for amino acid substitutions were carried out and calculation of significance were selected on advanced PTM explorer search strategies. A list of 172 common modifications was selected and added to virtually cleaved and fragmented peptides searched against experimentally obtained MS/MS spectra [19]. Manual inspection of spectra was carried out in the experiments reported.

LTQ Orbitrap MS

The LC-MS/MS analysis was carried out on an LTQ-Orbitrap Velos ETD mass spectrometer (Thermo Scientific, Waltham, MA, USA). The data acquisition software was XCalibur 2.1.0. The nanospray source of Proxeon (Thermo Scientific, Waltham, MA, USA) was used with the distal coated silica capillaries of New Objective (Woburn, MA, USA). The electrospray voltage was set to 1,500 V. The mass spectrometer was operated in positive ionization mode; the survey scan was performed in the orbitrap, recording a window between 400 and 1,800 m/z. The resolution was set to 60,000 for full MS and the automatic gain control was set to 1,000,000 ions with a maximal acquisition time of 500 ms. The instrument was operated in data-dependent acquisition mode. The minimum MS signal for triggering MS/MS was set to 500, and m/z values triggering fragmentation were put on an exclusion list for 30 s. In all cases one microscan was recorded and a maximum of 20 MS/MS experiments were triggered for the most intense ions from an MS scan. The lock mass option was enabled, and polydimethylcyclosiloxane (protonated (Si(CH3)2O)6; m/z 445.120025 Da) was used for internal recalibration of the mass spectra. CID was applied as fragmentation method with a target value of 1,000 in the linear ion trap, the maximal acquisition time was 100 ms, the collision energy was set to 35%, and the Q value to 0.25. An activation time of 10 ms was applied. Singly charged ions and ions with unassigned charge states were not fragmented. Helium was used as collision gas.

Raw spectra were processed by Mascot Daemon 2.2.2 (Matrix Science Ltd, London, UK), the search engine was Mascot 2.2.04. Peptide tolerance was set to ±2ppm, the MS/MS tolerance was set to 0.8 Da. Otherwise data mining was carried out as given above.

Results and Discussion

As shown in Fig. 1 the commercially available protein drug Avastin® was presenting with several spots. Heavy and light chain were clearly separated and heavy chain protein showed tracking while the light chain showed three major spots. Seven spots were picked and sequence coverages, enzyme that generated matching peptides, peptide sequences, ion scores and mass errors that were less than 0.2 Da are provided in Table S1 and Figure S1. Only spots 2,3,6 and 7 were presenting with tyrosine nitrations. The proposed multiple protein modifications (PMs) rather than sequence conflicts or amino acid exchanges observed in the individual spots resulting from HCT analysis respecting CID and ETD fragmentations may have been responsible for horizontal and vertical electrophoretic shifts as given in Table S2A.

LTQ-orbitrap analyses were used to find additional PMs in some Avastin® spots, and showed the presence of PMs and the results are demonstrated in Table S2B. PMs observed by both methods are presented in Table 1. Results on different modifications of avastin® expression forms are assigned to spot numbers.

Table 2 shows tyrosine nitrations shown by ion trap using CID but not by ETD fragmentation as well as using LTQ orbitrap.

thumbnail
Table 2. Identified nitrotyrosine or aminotyrosine modifications in Avastin by HCT and Orbitrap: the software proposes possible modifications on the peptide and subsequently assigns them to “measured m/z”. The theoretical m/z indicates the peptide mass with expected modifications.

https://doi.org/10.1371/journal.pone.0034511.t002

On the light chain as well as on the heavy chain of the antibody (Avastin®) LTQ identified this PM. HCT analysis demonstrated two tyrosine nitrations on the light chain and three at the heavy chain. LTQ orbitrap detected five tyrosine nitrations on the light chain and four on the heavy chain. Nitration was observed as nitration or as aminotyrosine [20]. Both MS/MS methods detected nitration of Y192 expressed by nitrotyrosine and aminotyrosine identification.

To support the identification of nitrotyrosine, Avastin® was reduced by sodium hydrosulfite and indeed, aminotyrosine on Y192 was detected (Figure S2), which does not rule out that the other modifications are not valid: results from different methodologies depend on fragmentation and formation of corresponding ions generated. Misidentifications of tyrosine nitration by a series of factors was ruled out [21].

Multiple nitrations of the humanised antibody Avastin® may have chemical and biological consequences: potential changes of Avastin immunochemistry may include antigenic changes and nitration has been repeatedly shown to modify this immunological property and was even leading to autoimmune phenomena [22]. The underlying cause of nitrations cannot be addressed but chemical modification by manufacturing is as plausible as nitration that occurred in vivo during primary generation of the antibody as a posttranslational modification [23]. Details from manufacturing and production are not available from the supplier or the corresponding patent (6,054,297 US patent, 2000).

Antibodies against nitrotyrosine have been observed [24] and it is known that nitrated peptides and proteins are eliciting antibody formation [25]-[27]. Moreover, antibodies against nitrated alpha synuclein produced an inflammatory response in mice that led to degeneration of dopaminergic neurons [28]. One may also suggest that nitration not only leads to autoantibody formation but also to conformational changes of the nitrated protein [29] that in turn may change antigenic properties and also protein-protein interactions with unknown functional consequences. Apart from nitration-induced antigenic changes of epitopes, nitration is known to impair function of proteins including Mn superoxide dismutase [30], [31].

A major finding indicating pathogenetic or toxic properties of nitrated proteins was presented recently: assembly of alpha-synuclein and fibrinogen were deteriorated by nitration of only a small fraction of proteins [25], [32]. As for fibrinogen, nitration is accelerating the rate of fibrin clot formation [33]. It cannot be ruled out, therefore, that nitration of Avastin® may lead to side effects based upon probable disturbed protein-protein interactions as aggregations that in turn may lead to a series of complications as listed in the drug information sheet.

As to the underlying cause of tyrosine nitration it remains open, whether it can be considered as a post-translational modification of the immunoglobulin Avastin® or technical in nature, or both [34]-[38].

Taken together, it remains unclear if the observed nitrations and other PMs detected on Avastin® may be responsible for different biological or pharmacotoxicological properties and effects. Quantification of nitrations and their presence in several batches of the product has to be taken into considerations on probable toxicity as well, but corresponding in vivo analyses based upon these findings should be carried out by the manufacturers to probably save this protein drug that may have strong potential in tumor therapy.

Supporting Information

Figure S1.

Sequence information of Avastin® is shown. - identified by A) HCT and B) Orbitrap.

https://doi.org/10.1371/journal.pone.0034511.s001

(PDF)

Figure S2.

Spectra of aminotyrosine and nitrotyrosine modifications.

https://doi.org/10.1371/journal.pone.0034511.s002

(PDF)

Table S1.

MS/MS results of from Avastin (MASCOT) identified by HCT (7 spots) and by Orbitrap (4 spots).

https://doi.org/10.1371/journal.pone.0034511.s003

(PDF)

Table S2.

The modifications revealed by the Modiro search engine from HCT and Orbitrap data.

https://doi.org/10.1371/journal.pone.0034511.s004

(PDF)

Author Contributions

Conceived and designed the experiments: GL. Performed the experiments: JW W-QC KL. Analyzed the data: JW W-QC. Contributed reagents/materials/analysis tools: EC. Wrote the paper: JW GL.

References

  1. 1. Bookman MA (2010) The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer. Ann Oncol 21: Suppl 7vii211–217.MA Bookman2010The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer.Ann Oncol21Suppl 7vii211217
  2. 2. Nagpal S, Harsh G, Recht L (2011) Bevacizumab improves quality of life in patients with recurrent glioblastoma. 2011. Chemother Res Pract: 602812. 602812 p.S. NagpalG. HarshL. Recht2011Bevacizumab improves quality of life in patients with recurrent glioblastoma.2011Chemother Res Pract602812602812
  3. 3. Nuijten M, Heigener DF, Bischoff HG, Chouaid C, Vergnenegre A, et al. (2010) Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 69: Suppl 1S4–10.M. NuijtenDF HeigenerHG BischoffC. ChouaidA. Vergnenegre2010Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.Lung Cancer69Suppl 1S410
  4. 4. Smith I, Pierga JY, Biganzoli L, Cortes-Funes H, Thomssen C, et al. (2011) Final overall survival results and effect of prolonged (>/ = 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat 130: 133–143.I. SmithJY PiergaL. BiganzoliH. Cortes-FunesC. Thomssen2011Final overall survival results and effect of prolonged (>/ = 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial.Breast Cancer Res Treat130133143
  5. 5. Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, et al. (2010) A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist 15: 845–851.CG WillettDG DudaM. AncukiewiczM. ShahBG Czito2010A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.Oncologist15845851
  6. 6. Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. Jama 305: 487–494.V. RanpuraS. HapaniS. Wu2011Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.Jama305487494
  7. 7. Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79: 27–38.S. HapaniA. SherD. ChuS. Wu2010Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.Oncology792738
  8. 8. Randall LM, Monk BJ (2010) Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 117: 497–504.LM RandallBJ Monk2010Bevacizumab toxicities and their management in ovarian cancer.Gynecol Oncol117497504
  9. 9. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23: 460–468.V. RanpuraB. PulipatiD. ChuX. ZhuS. Wu2010Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.Am J Hypertens23460468
  10. 10. Stone RL, Sood AK, Coleman RL (2010) Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 11: 465–475.RL StoneAK SoodRL Coleman2010Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.Lancet Oncol11465475
  11. 11. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM (2010) Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 15: 130–141.C. VaklavasD. LenihanR. KurzrockAM Tsimberidou2010Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?Oncologist15130141
  12. 12. Van Meter ME, Kim ES (2010) Bevacizumab: current updates in treatment. Curr Opin Oncol 22: 586–591.ME Van MeterES Kim2010Bevacizumab: current updates in treatment.Curr Opin Oncol22586591
  13. 13. Wozel G, Sticherling M, Schon MP (2010) Cutaneous side effects of inhibition of VEGF signal transduction. J Dtsch Dermatol Ges 8: 243–249.G. WozelM. SticherlingMP Schon2010Cutaneous side effects of inhibition of VEGF signal transduction.J Dtsch Dermatol Ges8243249
  14. 14. Wu S, Kim C, Baer L, Zhu X (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21: 1381–1389.S. WuC. KimL. BaerX. Zhu2010Bevacizumab increases risk for severe proteinuria in cancer patients.J Am Soc Nephrol2113811389
  15. 15. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, et al. (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21: 1804–1809.M. ReckJ. von PawelP. ZatloukalR. RamlauV. Gorbounova2010Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).Ann Oncol2118041809
  16. 16. Chen YH, Wu PC, Shiea J, Lo LH, Wu YC, et al. (2009) Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months. J Ocul Pharmacol Ther 25: 65–69.YH ChenPC WuJ. ShieaLH LoYC Wu2009Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months.J Ocul Pharmacol Ther256569
  17. 17. Chen WQ, Priewalder H, John JP, Lubec G (2010) Silk cocoon of Bombyx mori: proteins and posttranslational modifications—heavy phosphorylation and evidence for lysine-mediated cross links. Proteomics 10: 369–379.WQ ChenH. PriewalderJP JohnG. Lubec2010Silk cocoon of Bombyx mori: proteins and posttranslational modifications—heavy phosphorylation and evidence for lysine-mediated cross links.Proteomics10369379
  18. 18. Sokolovsky M, Riordan JF, Vallee BL (1967) Conversion of 3-nitrotyrosine to 3-aminotyrosine in peptides and proteins. Biochem Biophys Res Commun 27: 20–25.M. SokolovskyJF RiordanBL Vallee1967Conversion of 3-nitrotyrosine to 3-aminotyrosine in peptides and proteins.Biochem Biophys Res Commun272025
  19. 19. Kang SU, Fuchs K, Sieghart W, Pollak A, Csaszar E, et al. (2009) Gel-based mass spectrometric analysis of a strongly hydrophobic GABAA-receptor subunit containing four transmembrane domains. Nat Protoc 4: 1093–1102.SU KangK. FuchsW. SieghartA. PollakE. Csaszar2009Gel-based mass spectrometric analysis of a strongly hydrophobic GABAA-receptor subunit containing four transmembrane domains.Nat Protoc410931102
  20. 20. Balabanli B, Kamisaki Y, Martin E, Murad F (1999) Requirements for heme and thiols for the nonenzymatic modification of nitrotyrosine. Proc Natl Acad Sci U S A 96: 13136–13141.B. BalabanliY. KamisakiE. MartinF. Murad1999Requirements for heme and thiols for the nonenzymatic modification of nitrotyrosine.Proc Natl Acad Sci U S A961313613141
  21. 21. Stevens SM Jr, Prokai-Tatrai K, Prokai L (2008) Factors that contribute to the misidentification of tyrosine nitration by shotgun proteomics. Mol Cell Proteomics 7: 2442–2451.SM Stevens JrK. Prokai-TatraiL. Prokai2008Factors that contribute to the misidentification of tyrosine nitration by shotgun proteomics.Mol Cell Proteomics724422451
  22. 22. Ischiropoulos H (2009) Protein tyrosine nitration—an update. Arch Biochem Biophys 484: 117–121.H. Ischiropoulos2009Protein tyrosine nitration—an update.Arch Biochem Biophys484117121
  23. 23. Abello N, Kerstjens HA, Postma DS, Bischoff R (2009) Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins. J Proteome Res 8: 3222–3238.N. AbelloHA KerstjensDS PostmaR. Bischoff2009Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins.J Proteome Res832223238
  24. 24. Thomson L, Christie J, Vadseth C, Lanken PN, Fu X, et al. (2007) Identification of immunoglobulins that recognize 3-nitrotyrosine in patients with acute lung injury after major trauma. Am J Respir Cell Mol Biol 36: 152–157.L. ThomsonJ. ChristieC. VadsethPN LankenX. Fu2007Identification of immunoglobulins that recognize 3-nitrotyrosine in patients with acute lung injury after major trauma.Am J Respir Cell Mol Biol36152157
  25. 25. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985–989.BI GiassonJE DudaIV MurrayQ. ChenJM Souza2000Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.Science290985989
  26. 26. Heijnen HF, van Donselaar E, Slot JW, Fries DM, Blachard-Fillion B, et al. (2006) Subcellular localization of tyrosine-nitrated proteins is dictated by reactive oxygen species generating enzymes and by proximity to nitric oxide synthase. Free Radic Biol Med 40: 1903–1913.HF HeijnenE. van DonselaarJW SlotDM FriesB. Blachard-Fillion2006Subcellular localization of tyrosine-nitrated proteins is dictated by reactive oxygen species generating enzymes and by proximity to nitric oxide synthase.Free Radic Biol Med4019031913
  27. 27. Xu S, Ying J, Jiang B, Guo W, Adachi T, et al. (2006) Detection of sequence-specific tyrosine nitration of manganese SOD and SERCA in cardiovascular disease and aging. Am J Physiol Heart Circ Physiol 290: H2220–2227.S. XuJ. YingB. JiangW. GuoT. Adachi2006Detection of sequence-specific tyrosine nitration of manganese SOD and SERCA in cardiovascular disease and aging.Am J Physiol Heart Circ Physiol290H22202227
  28. 28. Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, et al. (2008) Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 3: e1376.EJ BennerR. BanerjeeAD ReynoldsS. ShermanVM Pisarev2008Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.PLoS One3e1376
  29. 29. Savvides SN, Scheiwein M, Bohme CC, Arteel GE, Karplus PA, et al. (2002) Crystal structure of the antioxidant enzyme glutathione reductase inactivated by peroxynitrite. J Biol Chem 277: 2779–2784.SN SavvidesM. ScheiweinCC BohmeGE ArteelPA Karplus2002Crystal structure of the antioxidant enzyme glutathione reductase inactivated by peroxynitrite.J Biol Chem27727792784
  30. 30. MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS, Thompson JA (1996) Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci U S A 93: 11853–11858.LA MacMillan-CrowJP CrowJD KerbyJS BeckmanJA Thompson1996Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts.Proc Natl Acad Sci U S A931185311858
  31. 31. MacMillan-Crow LA, Thompson JA (1999) Tyrosine modifications and inactivation of active site manganese superoxide dismutase mutant (Y34F) by peroxynitrite. Arch Biochem Biophys 366: 82–88.LA MacMillan-CrowJA Thompson1999Tyrosine modifications and inactivation of active site manganese superoxide dismutase mutant (Y34F) by peroxynitrite.Arch Biochem Biophys3668288
  32. 32. Parastatidis I, Thomson L, Burke A, Chernysh I, Nagaswami C, et al. (2008) Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem 283: 33846–33853.I. ParastatidisL. ThomsonA. BurkeI. ChernyshC. Nagaswami2008Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor.J Biol Chem2833384633853
  33. 33. Vadseth C, Souza JM, Thomson L, Seagraves A, Nagaswami C, et al. (2004) Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. J Biol Chem 279: 8820–8826.C. VadsethJM SouzaL. ThomsonA. SeagravesC. Nagaswami2004Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species.J Biol Chem27988208826
  34. 34. Ischiropoulos H, Beckman JS (2003) Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 111: 163–169.H. IschiropoulosJS Beckman2003Oxidative stress and nitration in neurodegeneration: cause, effect, or association?J Clin Invest111163169
  35. 35. Szabo C, Ischiropoulos H, Radi R (2007) Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6: 662–680.C. SzaboH. IschiropoulosR. Radi2007Peroxynitrite: biochemistry, pathophysiology and development of therapeutics.Nat Rev Drug Discov6662680
  36. 36. Reynolds MR, Berry RW, Binder LI (2007) Nitration in neurodegeneration: deciphering the "Hows" "nYs". Biochemistry 46: 7325–7336.MR ReynoldsRW BerryLI Binder2007Nitration in neurodegeneration: deciphering the "Hows" "nYs".Biochemistry4673257336
  37. 37. Lin HL, Kent UM, Zhang H, Waskell L, Hollenberg PF (2003) Mutation of tyrosine 190 to alanine eliminates the inactivation of cytochrome P450 2B1 by peroxynitrite. Chem Res Toxicol 16: 129–136.HL LinUM KentH. ZhangL. WaskellPF Hollenberg2003Mutation of tyrosine 190 to alanine eliminates the inactivation of cytochrome P450 2B1 by peroxynitrite.Chem Res Toxicol16129136
  38. 38. Lin HL, Zhang H, Waskell L, Hollenberg PF (2005) The highly conserved Glu149 and Tyr190 residues contribute to peroxynitrite-mediated nitrotyrosine formation and the catalytic activity of cytochrome P450 2B1. Chem Res Toxicol 18: 1203–1210.HL LinH. ZhangL. WaskellPF Hollenberg2005The highly conserved Glu149 and Tyr190 residues contribute to peroxynitrite-mediated nitrotyrosine formation and the catalytic activity of cytochrome P450 2B1.Chem Res Toxicol1812031210